Our Services

Molecular Imaging


Metabolic imaging using F-18 Fluorodeoxyglucose (FDG) and PET/CT has become the cornerstone of oncologic imaging and has been shown to be useful in tumor staging and follow-up. FDG PET/CT has also proven useful in predicting prognosis and treatment response. In certain diseases, such as lymphoma, higher FDG uptake is an indication of a higher grade malignancy. It is the most accurate, non-invasive imaging modality to differentiate between a benign and malignant tumour, sparing patients the painful diagnostic surgeries and suggesting treatment options earlier in the course of the disease.


PET & Fused PET/CT images in a
case of Hodgkin’s Lymphoma


1. *NSCLC pre-therapy
2. *NSCLC disease progression
*NSCLC – Non-Small Cell Lung Cancer


PET & Fused PET/CT scan in
patient with oesophageal cancer


PET & Fused PET/CT images in a
case of wide spread of metastases


We provide non-FDG PET/CT scans that are particularly effective for the molecular imaging of specific diseases.


C11-Acetate: Tumor identified in liver


18F FDG: No Tumour visualized


Compared with the FCH PET scan, the FDG PET scan under-estimates the bone metastic disease burden

C11-Acetate For Liver Cancer PET/CT Scan

  • Some tumours, such as hepatocellular carcinoma (HCC), are not detected    well with common tracer 18F-FDG.
  • A combination of FDG and C11-Acetate shows incremental value when compared to single-tracer imaging in the diagnosis of HCC.

F-18 Fluoromethylcholine (FCH) For Prostate Cancer PET/CT Scan

  • FCH is superior to FDG for the detection of extensive bone metastases from prostate cancer
  • Recommendations for use of F18-FCH PET imaging in prostate cancer include:
    • Targeting biopsy in high-risk men with persistently elevated PSA and repeated negative biopsy
    • Selection of patients for salvage radiotherapy.